Meloxicam: selective COX-2 inhibition in clinical practice

Area of Science:

• Pharmacology
• Gastroenterology
• Rheumatology

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) target cyclooxygenase (COX) enzymes.
• COX-2 inhibition is linked to anti-inflammatory effects, while COX-1 inhibition causes gastrointestinal and renal side effects.
• Meloxicam is a relatively selective COX-2 inhibitor.

Purpose of the Study:

• To evaluate the anti-inflammatory efficacy and gastrointestinal tolerability of meloxicam compared to other NSAIDs.
• To assess the safety profile of meloxicam, particularly its gastrointestinal and renal effects.

Main Methods:

• Volunteer studies assessing renal prostaglandin E2 excretion and platelet aggregation.
• Double-blind, randomized trials in osteoarthritis and rheumatoid arthritis patients.
• Double-blind, placebo-controlled trials and global safety analyses of clinical trials.

Main Results:

• Meloxicam (7.5 mg) did not inhibit renal prostaglandin E2 excretion or platelet aggregation, unlike indomethacin.
• Equivalent anti-inflammatory efficacy was observed between meloxicam and diclofenac, naproxen, and piroxicam in arthritis patients.
• Meloxicam demonstrated significantly less gastrointestinal damage and toxicity compared to piroxicam and diclofenac in clinical trials.

Conclusions:

• Relatively selective COX-2 inhibition, as exemplified by meloxicam, provides effective symptom relief.
• Meloxicam offers an improved gastrointestinal tolerability profile compared to non-selective NSAIDs.
• The renal safety and liver function profile of meloxicam is comparable to other available NSAIDs.